Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

Phase 2 Unknown 89 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University

Non-randomizedSingle-groupOpen-labelPrevention

Summary

A multi-cohort, open-label, multicenter exploratory clinical study of Bemalenograstim alfa for the prevention of reduced absolute neutrophil count(ANC) in patients with colorectal cancer/pancreatic cancer following a bi-weekly chemotherapy regimen.A total of 89 patients are planned to be enrolled.

Timeline

Start: 2023-11-30
Primary completion: 2024-10-30
Completion: 2025-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	F-627	Protein / enzyme biologic	20 mg	Subcutaneous

Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

Summary

Timeline

Drugs

Indications